-+ 0.00%
-+ 0.00%
-+ 0.00%

BeOne Medicines’ Tevimbra Combination Extends Median Survival to 27 Months in Gastroesophageal Cancer Trial

PUBT·10/23/2026 14:17:05
BeOne Medicines’ Tevimbra Combination Extends Median Survival to 27 Months in Gastroesophageal Cancer Trial
  • BeOne Medicines reported sustained survival benefits for Tevimbra with Ziihera and chemotherapy in first-line HER2-positive advanced gastroesophageal adenocarcinoma.
  • Patients lived longer than with trastuzumab-based chemotherapy; the benefit over Ziihera with chemotherapy alone did not reach statistical significance.
  • No new safety signals emerged in the Phase 3 HERIZON-GEA-01 trial.
  • The results will be presented today at the European Society for Medical Oncology Congress 2026 in Madrid.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20261023068473) on October 23, 2026, and is solely responsible for the information contained therein.